

1 **Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023 respiratory season in**
2 **the Netherlands**

3 **Authors:** Gesa Carstens*, Eva Kozanli*, Kirsten Bultink, Scott McDonald, Mansoer Elahi, Jordy de Bakker,
4 Maarten Schipper, Rianne van Gageldonk-Lafeber, Susan van den Hof, Albert Jan van Hoek† and Dirk
5 Eggink†

6 *These authors contributed equally

7 †Corresponding authors

8 **Affiliations:** Dutch National Institute for Public Health and the Environment (RIVM), Centre for
9 Infectious Disease Control (CIb), Bilthoven, The Netherlands

10 **Corresponding authors:** Dirk Eggink (dirk.eggink@rivm.nl) and Albert Jan van Hoek
11 (albert.jan.van.hoek@rivm.nl)

12 **Running Title:** Co-infections of SARS-CoV-2 with respiratory viruses

13

14 **Highlights**

15 Our study showed viral co-infections in 11% of the SARS-CoV-2 positive participants

16 SARS-CoV-2 mono-infections led to more severe symptoms than the common cold mono-infections
17 with seasonal coronavirus or rhinovirus

18 SARS-CoV-2 co-infections with common cold viruses did not lead to worse health status compared to
19 SARS-CoV-2 mono-infections

20 Odds for mono-infection with common cold virus were higher than for co-infection with SARS-CoV-2
21 and the respective common cold virus

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 **Objectives:** Evaluation of the presence and effect of SARS-CoV-2 co-infections on disease severity.

25 **Methods:** We collected both symptom data and nose- and throat samples from symptomatic people
26 during the 2022/2023 respiratory season in a large participatory surveillance study in the Netherlands,
27 and tested these for 18 respiratory viruses including SARS-CoV-2. We compared reported health status,
28 symptoms and odds of having a mono respiratory viral infection or co-infection with SARS-CoV-2 and
29 another respiratory virus.

30 **Results:** In total 4,655 samples were included with 22% (n=1,017) testing SARS-CoV-2 positive. Of these
31 11% (n=116) also tested positive for a second respiratory virus. The most frequently occurring co-
32 infections in SARS-CoV-2 positive participants were with rhinovirus (59%; n=69), seasonal coronaviruses
33 (15%; n=17) and adenovirus (7%; n=8). Participants with a co-infection with one of these three viruses
34 did not report more severe disease compared to those with a SARS-CoV-2 mono-infection. The odds of
35 experiencing SARS-CoV-2 co-infection with seasonal coronavirus or rhinovirus were lower compared to
36 the odds of the respective non-SARS-CoV-2 mono-infection (OR: 0.16, CI 95%: 0.10 – 0.24; OR: 0.21 CI
37 95%: 0.17 – 0.26; respectively).

38 **Conclusions:** SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and adenovirus are
39 frequently observed in the general population, but are not associated with more severe disease
40 compared to SARS-CoV-2 mono-infections. Furthermore, we found indications for inter-virus interaction
41 with rhinovirus and seasonal coronavirus, possibly decreasing risk of co-infection.

42

43 **Keywords:** Co-infection, mono-infection, SARS-CoV-2, rhinovirus, adenovirus, seasonal coronavirus,
44 viral interference, disease severity, viral load

45 INTRODUCTION

46 The transition of SARS-CoV-2 from pandemic status to endemicity introduced a complex landscape of
47 viral co-circulation, involving not only different SARS-CoV-2 variants but also other respiratory viruses
48 including rhinovirus, influenza virus, adenovirus, respiratory syncytial virus and endemic seasonal
49 coronaviruses. This situation necessitates an examination of prevalence of co-infections, its clinical
50 implications including disease severity, the potential for novel transmission dynamics, and the
51 consequential effects on human susceptibility to a range of viral pathogens.

52 Co-infections involving SARS-CoV-2 and other respiratory viruses have the potential to modify the
53 clinical manifestation of disease. This makes it more difficult to diagnose and treat these patients. For
54 COVID-19 patients, co-infections are seen in some severe cases (1). In addition, it has been suggested
55 that Influenza A and SARS-CoV-2 co-infections are associated with an increased risk for severe disease
56 and death compared to SARS-CoV-2 mono-infection (2).

57 Furthermore, this co-circulation could instigate new inter-virus dynamics, with SARS-CoV-2 infection
58 possibly augmenting or diminishing the susceptibility of individuals to other viral infections, thereby
59 influencing their transmission dynamics (3). There are open questions regarding the implications of this
60 co-circulation for the burden of illness, and whether additional public health measures, such as
61 vaccination programs targeting multiple viruses, might be warranted.

62 To investigate these questions, we conducted a study during the 2022/2023 respiratory season which
63 involved collecting nose and throat swabs by self-sampling from symptomatic individuals in a
64 participatory surveillance cohort in the Netherlands. Samples were tested for SARS-CoV-2 and 18 other
65 respiratory viruses using multiplex PCR. This approach resulted in a comprehensive dataset in which the
66 relationships between SARS-CoV-2 and other co-circulating respiratory viruses could be determined,
67 with particular focus on comparisons between SARS-CoV-2 mono-infection and co-infection with a
68 second respiratory virus in terms of the severity of illness and the set of presented symptoms, as well
69 as an exploratory assessment of susceptibility to co-infection with specific viruses. Specifically, we
70 wished to determine: (i) does SARS-CoV-2 co-infection with another respiratory virus lead to poorer
71 health during the infection (as measured by self-reported health status during the infection episode)
72 compared to the respective mono-infection with another virus or SARS-CoV-2? and (ii) Is there a
73 difference in the odds of infection with other respiratory viruses between participants who tested
74 positive and those who tested negative for SARS-CoV-2?

75

76

77 **METHODS**

78 **Data sources**

79 For this study we used a digital participatory surveillance system *Infectieradar* which was set up in March
80 2020 in the Netherlands as surveillance system for respiratory diseases independent of health care
81 seeking behavior. A rapid antigen self-test and self-sampling component was added to the platform in
82 the season 2022/2023 enabling pathogen identification in symptomatic or SARS-CoV-2 self-test positive
83 participants. The design has been described in detail previously (4, 5). Briefly, upon registration
84 participants fill in an intake questionnaire collecting sociodemographic and medical background data.
85 Subsequently, participants receive weekly questionnaires asking whether they experienced symptoms
86 consistent with an acute respiratory infection (ARI) and whether they had taken a SARS-CoV-2 self-test.
87 Symptomatic participants are asked to perform a SARS-CoV-2 self-test and to answer additional
88 questions regarding their symptoms, healthcare seeking behavior and health status in the previous
89 week.

90 A self-sampled nose throat swab (NTS) was requested from a random sample of participants that
91 reported ARI symptoms, i.e. sore throat, cough, runny nose, or dyspnea which had a symptom onset
92 within five days of reporting. The NTS was tested for 18 circulating respiratory viruses.

93 Moreover, participants who report symptoms consecutively in more than one weekly questionnaire are
94 asked whether the present symptoms belong to the same infection episodes as the previous symptoms.
95 Therefore, participants can report symptoms and their health status more than once per infection
96 episode and each participant can experience several infection episodes throughout the study period.

97

98 **Inclusion/exclusion criteria**

99 For this study, we included all participants submitting at least one weekly questionnaire in the
100 respiratory season 2022/2023 (October 1st 2022 to April 30th 2023). Next, swabs were excluded from
101 participants who were not invited and did not have ARI symptoms with onset within 5 days of reporting.
102 For the analysis of the self-sampled swabs, only participants submitting an NTS at least once during the
103 study period were included. Participants could have sent in more than one NTS during the study period,
104 but only one NTS per infection episode.

105

106 **Laboratory assays/testing methods**

107 Laboratory methods have been previously described (4). In short, swabs were collected in virus transport
108 medium and RNA extraction was performed using MagNApure 96 (MP96) (Roche). Extracted RNA was
109 subsequently analyzed for the presence of the following respiratory viruses: SARS-CoV-2, influenza A,
110 influenza B, RSV-A, RSV-B, human metapneumovirus, rhino-/enterovirus, adenovirus, parainfluenza-1,
111 parainfluenza-2, parainfluenza-3, parainfluenza-4, bocavirus, seasonal coronavirus NL63, seasonal

112 coronavirus HKU1, seasonal coronavirus OC43, seasonal coronavirus 229E and MERS-CoV, using SARS-
113 CoV-2 specific RT-PCR as described (6) and multiplex real-time PCR (RespiFinder 2SMART, PathoFinder,
114 the Netherlands).. Although the RespiFinder cannot officially differentiate between rhino-/enterovirus,
115 additional in-house typing of a representative subset of samples has shown that the majority of these
116 samples are rhinovirus positive. Therefore, in the main text and results we present them as rhinovirus.
117 Samples that test positive for only one pathogen by these assays are considered mono-infections.
118 Bacterial infections or carriage are not considered for this study.

119

120 **Primary outcome variable**

121 The main outcome variable was self-reported health status, which was measured in weekly
122 questionnaires. Participants were asked to rate how good or bad their health was in the last week on a
123 scale of 0 to 100, where 100 represented the best imaginable state of health and 0 represented the
124 worst imaginable state of health.

125

126 **Exposure variable and covariates**

127 The exposure variable was 'infection status' (consisting of: SARS-CoV-2 mono-infection, co-infection
128 SARS-CoV-2 with rhinovirus, co-infection SARS-CoV-2 with adenovirus and co-infection SARS-CoV-2 with
129 seasonal coronaviruses). The following baseline characteristics were included as covariates in
130 multivariable analysis: sex, age-group (<30, 30-39, 40-49, 50-64; 65+ years), education level
131 (none/primary only, middle, higher (i.e., university qualification)), presence of children aged <5 years in
132 the household, presence of children aged 5-18 years in the household (both binary variables), smoker
133 status (non-smoker, ever-smoker), hay fever and/or other allergies and regular use of medication for
134 selected underlying conditions (lung disease (e.g., emphysema, COPD), cardiovascular disease, diabetes;
135 all coded as binary variables).

136

137 **Descriptive analysis**

138 We report the observed distribution over the various detected respiratory viruses within our analysis
139 period, and graphically show the temporal characteristics of the detected mono- and co-infections. We
140 describe the distribution of reported symptoms (both ARI symptoms and other possible symptoms),
141 comparing SARS-CoV-2 mono-infection, SARS-CoV-2 co-infection with rhinovirus, co-infection with
142 adenovirus, co-infection with seasonal coronaviruses, and mono-infections with rhinovirus, adenovirus,
143 and seasonal coronaviruses. Reported symptoms from more than one weekly questionnaire per
144 infection episode were pooled.

145

146 **Association between participant characteristics and self-reported health status**

147 We performed univariable and multivariable analyses to estimate differences in self-reported health
148 status among all symptomatic individuals within this study population. For this, we used a generalized
149 linear mixed effects model. We incorporated a random intercept for participant ID to account for
150 variation within participants and added a natural spline with three knots to account for time difference
151 between symptom onset and submitting a weekly questionnaire capturing potential variations in health
152 status over the disease course. The multivariable regression model was adjusted for all demographic
153 and comorbidity variables as previously specified.

154

155 **Comparison of reported health status between mono- and co-infections with SARS-CoV-2 and** 156 **respiratory viruses**

157 We used the same generalized linear mixed effects model to estimate the differences in self-reported
158 health status among mono- and coinfecting individuals. Based on this, to visually compare the
159 associations of mono-infection and co-infections with SARS-CoV-2 and rhinovirus, adenovirus or
160 seasonal coronaviruses on the health status adjusted for confounders we computed and plotted
161 estimated-marginal means for the health status using the emmeans package (7). Next, we plotted the
162 marginal mean of the health status over time since symptom onset and stratified by age group for the
163 different mono- and co-infections to visually show the progression of the health status during infection.

164 In an alternative analysis, we analyzed only the lowest reported health status per participant infection
165 episode across mono- and co-infected persons to compare differences in perceived health during the
166 as most severe experienced phase of the infection.

167 **Exploratory assessment of viral load**

168 To study the possible association between viral load of SARS-CoV-2 mono-infections and co-infections,
169 we performed a linear regression model with Ct value as outcome variable and infection status as
170 independent variable with SARS-CoV-2 mono-infection as reference group. We performed univariate
171 and multivariate analyses, the latter corrected for age group and sex.

172

173 **Symptom analysis**

174 We performed multiple multivariable logistic regressions to assess the odds of experiencing various
175 respiratory or constitutional symptoms in case of a non-SARS-CoV-2 mono-infection or SARS-CoV-2 co-

176 infection, using SARS-CoV-2 mono-infection as reference group. The analyses were adjusted for age
177 group and sex.

178

179 Exploratory assessment of co-infection prevalence associated with SARS-CoV-2

180 We conducted multiple logistic regression analyses for infection with the most common mono-
181 infections; those with rhinovirus or with one of the seasonal coronaviruses. We compared the odds of
182 testing positive for either virus between participants who tested positive and those who tested negative
183 for SARS-CoV-2. The estimated odds ratio (OR) for co-infection with another virus can be interpreted as
184 the association of SARS-CoV-2 infection on susceptibility to that other virus and vice versa. This analysis
185 is necessarily exploratory because other, unmeasured factors could influence the odds of co-infection
186 (e.g., respiratory virus seasonality, and SARS-CoV-2 or influenza vaccination effectiveness).

187 All analyses were conducted using R statistical software, version 4.3.1 (8).

188

189 RESULTS

190 Participants and Sample collection

191 Within the analysis period (1 Oct 2022 through 30 April 2023), a total of 17,499 participants took part
192 in the *Infectieradar* self-swab study (Fig. S1). Of these, 12,968 (74%) reported ARI symptoms in at least
193 one weekly survey within 5 days of symptom onset, of which 3,498 (27%) reported a positive self-test
194 (Table 1). In total 4,689 NTS samples from 3,945 participants were included in this study and presence
195 of SARS-CoV-2 as well as other respiratory viruses was investigated.

196 Our study population had a higher proportion of females (57.2%) than males with the largest age group
197 being 50-64 years (Table 1). The youngest age group (<25) was underrepresented with only 3.3%. The
198 majority of our participants have completed higher education (59%).

199

200 **Table 1.** Characteristics of the Infectieradar study population and linked laboratory database.

Variable	Eligible Participants N (%)	Self-swabs sent in N (%)	Detections SARS-CoV-2 N (%)	Health status Median [IQR]	No. symptoms Median [IQR]
(Samples)	-	4,655	1,028	-	-
<i>Infection status</i>					
No infection	-	1,761 (38%)	-	71 [60, 81]	3 [2, 5]
SARS-CoV-2 mono-infection	-	907 (19%)	912 (89%)	63 [50, 75]	6 [4, 9]
Rhinovirus mono-infection	-	911 (20%)	-	70 [60, 81]	4 [2, 5]
Adenovirus mono-infection	-	25 (0.5%)	-	74 [64, 90]	3 [2, 6]

Seasonal coronaviruses mono-infection	-	329 (7%)	-	70 [58, 80]	4 [2, 5]
Co-infection SARS-CoV-2 and rhinovirus	-	69 (1.5%)	69 (6.7%)	65 [50, 75]	5 [3, 7]
Co-infection SARS-CoV-2 and adenovirus		8 (0.2%)	8 (0.8%)	60 [49, 70]	5 [3, 8]
Co-infection SARS-CoV-2 and seasonal coronaviruses	-	17 (0.4%)	17 (1.7%)	64 [51, 72]	5 [4, 7]
(Participants)	17,069	3,921	1,017		
Sex					
Female	9,748 (57%)	2,547 (65%)	638 (63%)	69 [53, 80]	4 [2, 6]
Male	7,289 (43%)	1,368 (35%)	377 (37%)	70 [57, 80]	4 [4, 7]
Age-group					
<25 yrs	486 (2.8%)	115 (2.9%)	21 (210%)	63 [50, 75]	5 [3, 8]
25-39 yrs	2,270 (13%)	672 (17%)	152 (15%)	67 [54, 78]	4 [3, 7]
40-49 yrs	2,727 (16%)	739 (19%)	192 (19%)	68 [51, 80]	4 [2, 6]
50-64 yrs	6,660 (39%)	1,519 (39%)	390 (38%)	70 [50, 80]	4 [2, 7]
65+ yrs	4,926 (29%)	876 (22%)	262 (26%)	70 [50, 84]	4 [2, 6]
Education level					
Lower/none	290 (1.7%)	44 (1.1%)	19 (1.9%)	70 [51, 80]	5 [3, 7]
Middle	6,583 (39%)	1,369 (35%)	386 (38%)	70 [54, 80]	4 [2, 7]
Higher	9,999 (59%)	2,469 (64%)	595 (60%)	70 [55, 80]	4 [2, 6]
Ever smoker	1,586 (9.3%)	288 (7.4%)	89 (8.8%)	69 [53, 80]	4 [3, 7]
Underlying condition					
Allergy(s)/hay fever	6,021 (35%)	1,536 (39%)	365 (36%)	68 [55, 80]	4 [2, 7]
Diabetes	686 (4.0%)	108 (2.8%)	26 (2.6%)	72 [56, 82]	4 [2, 5]
Chronic lung disease	457 (2.7%)	74 (1.9%)	22 (2.2%)	61 [50, 75]	4 [3, 7]
Cardiovascular disease	1,679 (9.8%)	313 (7.9%)	93 (9.1%)	69 [50, 80]	4 [2, 6]
Household composition					
1+ children <5 years	1,255 (7.4%)	356 (9.1%)	86 (8.5%)	70 [59, 80]	4 [2, 6]
1+ children 5-18 years	3,764 (22%)	968 (25%)	247 (24%)	68 [52, 80]	4 [2, 6]

Note. Participants can have more than one infection during the study period. CI = confidence interval. *Health status* and *number of symptoms* for the different participant characteristics are shown only for participants who sent in a nose- and throat swab.

201

202


203 Pathogen detection

204 1,028 (22%) of samples were SARS-CoV-2 positive measured by SARS-CoV-2 specific RT-PCR. Co-
 205 infection with at least one other respiratory virus was detected in 11% (116/1,028) of SARS-CoV-2
 206 positive samples. The most frequently occurring co-infections in SARS-CoV-2 positive participants were
 207 rhinovirus (59%; 69/116), seasonal coronaviruses (15%; 17/116), adenovirus (7%, 8/116) or other
 208 viruses (Table S1) (20%; 22/116, consisting of influenza A (2/22), influenza B (2/22), bocavirus (2/22),
 209 parainfluenza virus (5/22), respiratory syncytial virus (6/22) and human metapneumovirus (5/22)).The
 210 corresponding percentages of samples with detected mono-infection were SARS-CoV-2 (19%;

211 912/4,689), rhinovirus (20%; 923/4,689), adenovirus (0.5%; 25/4,689), and seasonal coronaviruses (7%;
 212 329/4,689).

213 Co-infections coincided with their respective mono-infection, as shown in Figure 1A and 1B, in which
 214 the mono- and co-infections are plotted during the 2022/2023 season.

215




216
 217 **Figure 1. Detected respiratory infections during the 2022/2023 respiratory season in Infectieradar in**
 218 **the Netherlands.** Detected mono-infections (A) and co-infections (B) over the analysis period (1 Oct
 219 2022 – 30 April 2023).
 220

221 **Health status and covariates in the Infectieradar population**

222 Reported health status was analyzed for the symptomatic study population. Most participants reported
 223 a health status higher than 50 out of 100 with only slight differences between sex (Fig. S2). We assessed
 224 the association between various covariates and self-reported health status by estimating beta

225 coefficients in both univariable and multivariable regression analyses (Fig. 2 and Table S2). The male sex
 226 was associated with reporting a higher health status (adjusted beta: 0.17, 95% CI 0.13 to 0.2), as can be
 227 seen in Figure 2. Also, age was associated with health status: compared to participants aged 50-64 years,
 228 participants of age group <25 and 25-39 were associated with reporting a lower health status (adjusted
 229 beta -0.13, 95% CI -0.22 to -0.04 and adjusted beta -0.13, 95% CI -0.18 to -0.08, respectively) while
 230 participants of the age group 65+ reported a higher health status (adjusted beta 0.11, 95% CI 0.07 to
 231 0.14). Moreover, participants with allergies and/or hay fever were associated with a lower health status
 232 (adjusted beta -0.08, 95% CI -0.11 to -0.05) as well as participants with diabetes (adjusted beta -0.1, 95%
 233 CI -0.19 to -0.02) and heart conditions (adjusted beta -0.17, 95% CI -0.23 to -0.12).

234



235 **Figure 2: Forest plot of beta coefficients of the linear regression model estimating the association**
 236 **between main participant characteristics with health status during infection.** Results of univariable
 237 and multivariable regression analyses for all symptomatic participants of our study population with 95%
 238 confidence interval.
 239

240


241

242 **Comparison self-reported health status between mono- and co-infected participants**

243 Using the results of all pathogen detections, we estimated the effect of having a mono-infection with
 244 SARS-CoV-2, adenovirus, rhinovirus and seasonal coronaviruses and having SARS-CoV-2 co-infections
 245 with one of those viruses on perceived health status during infection (Table S3). Figure 3 shows the
 246 estimated marginal mean of the health status of each infection. The mean health status was statistically

247 significantly higher for participants with a mono-infection with rhinovirus, seasonal coronaviruses or
248 adenovirus than for those with a SARS-CoV-2 mono-infection, suggesting more severe disease during
249 COVID-19 compared to more traditional respiratory viruses (often referred to as common cold viruses).
250 Interestingly, participants with a co-infection of one of these common cold viruses with SARS-CoV-2 had
251 a similar mean health status compared to participants with a SARS-CoV-2 mono-infection.

252
253
254
255




256 **Figure 3: Mean health status during infection.** Estimated marginal means of health status and 95%
257 Confidence level per infection. Horizontal line indicating the estimated-marginal mean health status for
258 participants with SARS-CoV-2 mono-infection infection.
259
260

261
262 Additionally, we observed that the estimated marginal mean health status varies over time depending
263 on the day since symptom onset (Fig. S3). Across all age groups and infections, the lowest health is
264 reported around day 4-6 since symptom onset before gradually increasing again, with older age groups
265 consistently reporting a higher health status during the whole infection episode compared to the lowest
266 age group. Due to the change in health status during disease progression we adjusted the main analysis
267 and performed an alternative analysis.

268 In this alternative analysis, we investigated the lowest reported health status per infection episode
269 instead of the mean health status in the model to compare severity during the most severe phase of
270 different infections as perceived by the participants (n = 4,950) instead of the health status over the
271 complete episode. All trends determined in the main analysis were similar in this analysis (Fig. 4 and

272 Table S4). Overall, we found SARS-CoV-2 cases more severe disease than traditional common cold
273 viruses, however SARS-CoV-2 co-infections do not cause worse health status compared to SARS-CoV-2
274 mono-infections.



275 **Figure 4. Results of the alternative analysis using only the lowest health status per infection period as**
276 **model input.** Estimated marginal means of the health status with 95% Confidence level per infection.
277 Horizontal line indicating the estimated-marginal mean health status for participants with SARS-CoV-2
278 mono-infection infection.
279
280

281
282 As no difference in disease severity was observed between SARS-CoV-2 mono-infections and co-
283 infections, it is interesting to investigate the effect of a co-infection on SARS-CoV-2 viral load. Viral load
284 has been related to disease severity before (9). And in addition, viral load might influence the risk of co-
285 infection. We therefore compared Ct values as a proxy of viral load between SARS-CoV-2 mono-
286 infections and co-infections. Mono-infections of SARS-CoV-2 are associated with a significantly lower Ct
287 value (p value < 0.01), reflecting higher viral load, as compared to co-infections with rhinovirus and SARS-
288 CoV-2 (mean Ct value: 22.3 and 24.0, respectively, Table S5). We could not confirm higher Ct values for
289 SARS-CoV-2 co-infections with adenovirus and coronaviruses (mean Ct value: 21.6 and 24.3,
290 respectively), likely caused by a lower number of cases.


291
292 **Difference in symptoms between mono- and co-infected individuals**

293 The median number of reported different symptoms of participants with SARS-CoV-2 mono-infection
294 was 6 [Interquartile range (IQR): 4-9], which was higher than reported by participants with other mono-
295 infections (rhinovirus: 4 [IQR 2-5]; adenovirus: 3 [IQR 2-6]; seasonal coronaviruses: 4 [IQR 2-5]) and co-

296 infections (co-infection SARS-CoV-2 with rhinovirus: 5 [IQR 3-7]; co-infection SARS-CoV-2 with
297 adenovirus: 5 [IQR 3-8]; co-infection SARS-CoV-2 with seasonal coronaviruses: 5 [IQR 4-7], Table 1). In
298 line with this, 40% (n = 365) of the participants with SARS-CoV-2 mono-infection took sick leave, while
299 sick leave was significantly less common among participants with other mono-infections (11% (n = 97),
300 p-value <0.001 for rhinovirus; 16% (n = 4), p-value 0.01 for adenovirus; and 10% (n = 32), p-value < 0.001
301 for seasonal coronavirus; Table S6). However, SARS-CoV-2 co-infected participants took sick leave
302 significantly more often than their mono-infected non-SARS-CoV-2 counterparts but not more than
303 participants with SARS-CoV-2 mono-infection (rhinovirus co-infection: 33% (n = 23), p-value 0.31;
304 adenovirus co-infection: 63% (n = 5), p-value 0.28; seasonal coronavirus co-infection: 35% (n = 6), p-
305 value 0.81).

306 Of the participants mono-infected with SARS-CoV-2, 87% reported rhinitis, as well as all participants co-
307 infected with adenovirus (100%) and 94% of participants co-infected with seasonal coronaviruses (Fig.
308 5). Cough, a sore throat and sneezing were also reported frequently by most participants. Compared to
309 SARS-CoV-2 mono-infection, the odds of experiencing respiratory or constitutional symptoms were
310 mainly similar for SARS-CoV-2 co-infected participants (Fig. S4). However, SARS-CoV-2 and rhinovirus
311 co-infected individuals had slightly lower odds of experiencing headache, sneeze, pain and chills.

312



313
 314 **Figure 5: Overview of symptom prevalence.** Percentage reported symptoms per infection (SARS-CoV-2
 315 mono-infection, SARS-CoV-2 co-infection with adenovirus, co-infection with rhinovirus, co-infection
 316 with seasonal coronaviruses, and mono-infection with rhinovirus, adenovirus, and seasonal
 317 coronaviruses) among all participants with lab samples ($n=3,963$). Numbers in the heatmap correspond
 318 to N (%). Colored boxes indicate symptoms that are significantly less reported (blue boxes) compared
 319 to the reference group SARS-CoV-2 mono-infection (black box). There were no symptoms which were
 320 significantly more often reported compared to the reference group.
 321


322

323 **Exploratory assessment of co-infection prevalence associated with SARS-CoV-2**

324 Next, we investigated whether infection with SARS-CoV-2 did alter the odds of infection with another
 325 respiratory virus (Fig. 6). Odds for co-infection with SARS-CoV-2 combined with either seasonal
 326 coronavirus or rhinovirus are lower than mono-infection with one of these non-SARS-CoV-2 viruses (OR:

327 0.16, CI 95%: 0,10 to 0.24, n = 17; OR: 0.21, CI 95%: 0.17 to 0.24, n = 69; respectively). The number of
328 adenovirus co-infections was too low to perform this analysis on.

329



330
331 **Figure 6: Odds ratio for co-infection with SARS-CoV-2 and other pathogens compared to SARS-CoV-2**
332 **mono-infection.** The plot shows odds ratios for co-infection with seasonal coronavirus (n=17) and
333 rhinovirus (n=69).
334

335

336 DISCUSSION

337 We examined the associations between respiratory mono-infections and co-infections with SARS-CoV-
338 2, and reported symptoms and perceived health in the Netherlands during the transition of SARS-CoV-
339 2 from a pandemic to an endemic virus. Co-infection of SARS-CoV-2 with another respiratory virus was
340 found in 11% of SARS-CoV-2 positive participants; these co-infections included mainly rhinovirus,
341 seasonal coronaviruses and adenovirus. Compared with SARS-CoV-2 mono-infection, participants' self-
342 reported health status for a mono-infection with these three common cold viruses was higher,
343 suggesting less severe disease. However, a co-infection of SARS-CoV-2 with these three common cold
344 viruses resulted in a similar health status compared to SARS-CoV-2 mono-infection. Across all mono-
345 and co-infections similar symptoms were reported with rhinitis, cough, sore throat and sneezing being
346 the most frequent symptoms. However, SARS-CoV-2 and rhinovirus co-infected individuals had lower
347 odds of experiencing headache, sneeze, pain and chills than individuals infected only with SARS-CoV-2.

348
349 A meta-analysis of studies reporting co-infection of SARS-CoV-2 with other respiratory viruses up to
350 August 2021 found a pooled co-infection prevalence of 5.01% (95% CI 3.34%–7.27%) among those with
351 SARS-CoV-2 (10). This is lower than the 11% we found in our study. However, our study period took
352 place between October 2022 and May 2023. During this period, there was a higher circulation of SARS-
353 CoV-2 (with omicron variants) (11) compared to the period before August 2021. Also, there were fewer
354 nonpharmaceutical interventions such as facemasks and social distancing measures in place, leading to
355 heightened circulation of all respiratory viruses and thus to a higher probability of (co-)infection (12).
356 This highlights the impact of temporal fluctuations and co-circulation of respiratory viruses on co-
357 infection rates, which may vary across different periods and geographic locations.

358 Interestingly, we observed low numbers of co-infections with influenza. Unlike the findings from a study
359 in Missouri, USA conducted between October 2021 and January 2022, in which a prevalence of 33% was
360 reported for influenza co-infection among persons with SARS-CoV-2 (13). Even though in the
361 Netherlands the 2022/2023 influenza season lasted until approximately week 11 (i.e., 13-19 March
362 2023) (11) we detected 110 Influenza mono-infections and only 4 influenza and SARS-CoV-2 co-
363 infections (Table S1).

364 There is limited literature on SARS-CoV-2 co-infections among those who do not seek health care. A
365 meta-analysis, in which the vast majority of included studies had been conducted among adult-patients
366 hospitalized for SARS-CoV-2, found an increased odds of mortality (OR=2.84; 95% CI: 1.42–5.66)
367 associated with bacterial, fungal or viral co-infection (14). This increase in severity in SARS-CoV-2 co-
368 infected patients compared to mono-infected patients is not confirmed with our results. We observed
369 that co-infected individuals reported a similarly perceived health status compared to participants mono-
370 infected with SARS-CoV-2, with a point estimate which indicates slightly less severe disease. However,
371 we only included co-infections with respiratory common cold viruses, and did not test for many bacteria
372 and fungi. Therefore, some of those labeled as SARS-CoV-2 mono-infections could have been co-
373 infected with one of those untested pathogens. Additionally, we observed that viral loads were lower
374 in co-infected individuals, which could have influenced why the health status was not more severe for
375 SARS-CoV-2 co-infections compared to SARS-CoV-2 mono-infections. Furthermore, these lowered viral
376 loads in the co-infection group could be an indication for inter-virus interaction.

377
378 In our exploratory analysis, we observed lower odds of experiencing SARS-CoV-2 co-infections with both
379 seasonal coronaviruses and rhinovirus compared to experiencing mono-infection with those non-SARS-
380 CoV-2 viruses. Seasonality of viruses might affect how much co-circulation of different respiratory

381 viruses occurs and therefore also affects the number of co-infections with these viruses and SARS-CoV-
382 2. A lack of co-circulation or co-infection between respiratory viruses can suggest interaction, i.e.
383 competition for susceptible hosts between those viruses or internal seasonality of those viruses (15).
384 During our study period in the respiratory season (October to May) we observed co-circulation of the
385 compared respiratory viruses with SARS-CoV-2 indicating the possibility of co-infections. However, our
386 exploratory assessment of the odds of SARS-CoV-2 co-infection indicates that we observed fewer cases
387 than expected based on the prevalence of the non-SARS-CoV-2 respiratory viruses. This finding could
388 suggest virus-virus interplay between SARS-CoV-2 and rhinovirus as well as seasonal coronaviruses. For
389 other pathogens numbers were too low to assess this in this study.

390 However, without knowing the timing of infection of the viruses in the host and the subsequent immune
391 response, it is difficult to understand the underlying mechanisms that influence SARS-CoV-2 interplay
392 with other respiratory viruses. Viral interference is often proposed as a cause for this interplay in which
393 case presence of one virus could inhibit entrance or replication of the other virus through mechanisms
394 of the virus itself, or of its host. Cellular overlap and for example use of similar receptors for cell entry
395 could affect co-infection rates (16, 17). Furthermore, it was previously suggested that as host innate
396 immunity, including interferon response, increases upon the first infection, susceptibility for a second
397 infection is altered (18). Previous studies have shown that the presence of rhinovirus in the respiratory
398 endothelium can block SARS-CoV-2 viral replication (19), while SARS-CoV-2 primary infection was shown
399 to not impact rhinovirus replication (20). Evidence for the interplay between seasonal coronaviruses
400 and SARS-CoV-2 is less clear: several studies have suggested that cross-immunity exists for SARS-CoV-2
401 and seasonal coronaviruses (17, 21), while other studies found increased SARS-CoV-2 infection
402 susceptibility and increased disease severity associated with pre-existing immunity for seasonal
403 coronaviruses (22). Although these interplays are likely to explain the reduced odds of SARS-CoV-2 co-
404 infection with seasonal coronaviruses or rhinovirus, a simplistic model can hardly capture these
405 dynamics. More intricate models require more information on the timing and dynamics of infections
406 and host responses to define virus interactions. Adding to the theory of viral interference, we observed
407 that co-infections of SARS-CoV-2 and rhinovirus have lower viral load than SARS-CoV-2 mono-infection.
408 This could mean that the presence of one virus could obstruct the susceptibility or efficient replication
409 of another virus. However, these findings should be further investigated to confirm viral interference.
410 To further explore this, *in vitro* studies might be more appropriate or cohort studies using dense
411 sampling allowing detection of viral dynamics, including low viral loads of co-infections. Additionally,
412 future work using sequential sampling could focus on the implications of the order of infection on the
413 susceptibility to acquire co-infection.

414 In this study, we found that less people called sick with a mono-infection compared to those with a co-
415 infection of these same viruses with SARS-CoV-2. This observation does not support an effect of
416 behavior, in the form of isolation, on co-infection susceptibility, as mono-infected individuals are not
417 more isolated than co-infected individuals. Moreover, we observed more sick leave for SARS-CoV-2
418 mono-infections as compared to other mono-infections. This suggests that SARS-CoV-2 infected
419 individuals may have experienced more severe disease, as also indicated by the reported health status.
420 However, as people had a self-test result, previous advice to stay at home when being infected, likely
421 also affected behavior.

422

423 The main strength of this study is the community-based population consisting of voluntary participants
424 from the *Infectieradar* surveillance system who self-tested for SARS-CoV-2 and present with mild
425 symptoms. Due to the weekly questionnaires and self-sampling, we were able to catch infections in an
426 early phase of the disease and collect information on perceived health and symptoms during the
427 infection. Potential limitations concern representativeness: compared with the general population,
428 *Infectieradar* participants are more likely to be female, ages 50-64 years are over-represented, and are
429 more highly educated and have lower prevalence of underlying health problems (5). Moreover, we
430 cannot estimate the role of behavior in co-infection prevalence. Self-reporting introduces biases in
431 perceived health status and could lead to missing cases because of more severe diseases being not
432 reported in *Infectieradar*. Furthermore, studying individuals with ARI symptoms can introduce selection
433 bias, as viral status and viral load may affect the probability of symptoms and consequently the
434 likelihood of individuals being included in the study population (23). Therefore, our observed odds ratios
435 of SARS-CoV-2 co-infections might not reflect the full population-level interactions between SARS-CoV-
436 2 and other respiratory viruses due to unknown selection probabilities.

437

438 In conclusion, we show that, within a cohort of the general population in the Netherlands in the
439 respiratory season of 2022 to 2023, SARS-CoV-2 co-infections with rhinovirus, seasonal coronavirus and
440 adenovirus did not lead to a worse perceived disease severity compared to SARS-CoV-2 mono-
441 infections. In our study the odds of experiencing SARS-CoV-2 co-infection with rhinovirus and seasonal
442 coronaviruses were lower than for experiencing the respective non-SARS-CoV-2 mono-infections,
443 suggesting a form of viral interference.

444

445 **Competing interests**

446 All authors of this manuscript declare no competing interests.

447

448 **Ethics**

449 The samples were collected as part of *Infectieradar*. The protocol for *Infectieradar* was approved by the
450 Medical Ethics Review Committee Utrecht (reference number: WAG/avd/20/008757; protocol 20-131)
451 was obtained given the nature of data collection. All participants provided informed consent upon
452 registration, which included agreement to the privacy statement and described the processing of
453 personal data and research results, website security measures taken, and how to file a complaint.
454 Participants were eligible to withdraw from the study at any time. Individuals had to be 16 years or over
455 to be able to participate.

456

457 **Funding:**

458 This work was supported by the ministry of Health, Welfare and Sports (VWS), the Netherlands. The
459 funders had no role in study design, data collection and analysis, decision to publish, or preparation of
460 the manuscript.

461

462 **Acknowledgements:**

463 We thank the participants of *Infectieradar* for their weekly contributions and submission of samples.
464 Without their contribution this project won't have been a success. Furthermore, we thank our
465 colleagues who help to maintain and run the *Infectieradar*-cohort and handling the samples. Developing
466 and running this study has been a huge team effort.

467 REFERENCES

- 468 1. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among
469 COVID-2019 cases. *Virus Research*. 2020;285:198005.
- 470 2. Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. Prevalence and associated outcomes of coinfection
471 between SARS-CoV-2 and influenza: a systematic review and meta-analysis. *International Journal of*
472 *Infectious Diseases*. 2023;136:29-36.
- 473 3. Wong A, Barrero Guevara LA, Goult E, Briga M, Kramer SC, Kovacevic A, et al. The interactions
474 of SARS-CoV-2 with cocirculating pathogens: Epidemiological implications and current knowledge gaps.
475 *PLoS Pathogens*. 2023;19(3):e1011167.
- 476 4. Smit T, Carstens G, Han W, Bultink K, Bakker Jd, Elahi M, et al. Flexible and scalable participatory
477 syndromic and virological surveillance for respiratory infections: our experiences in The Netherlands.
478 *medRxiv*. 2024:2024.04.24.24306278.
- 479 5. McDonald S, Wijngaard Cvd, Wielders C, Friesema I, Soetens L, Paolotti D, et al. Risk factors
480 associated with the incidence of self-reported COVID-19-like illness: data from a web-based syndromic
481 surveillance system in the Netherlands. *Epidemiology & Infection*. 2021;149:e129.
- 482 6. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
483 coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):2000045.
- 484 7. Lenth RV. emmeans: Estimated Marginal Means, aka Least-Squares Means 2024 [Available
485 from: <https://github.com/rvlenth/emmeans>].
- 486 8. R Core Team. R: A Language and Environment for Statistical Computing. 4.3.1 ed: R Foundation
487 for Statistical Computing; 2023.
- 488 9. Munker D, Osterman A, Stubbe H, Muenchhoff M, Veit T, Weinberger T, et al. Dynamics of SARS-
489 CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients. *Eur*
490 *Respir J*. 2021;58(1).
- 491 10. Krumbein H, Kümmel LS, Fragkou PC, Thölken C, Hünenbein BL, Reiter R, et al. Respiratory viral
492 co-infections in patients with COVID-19 and associated outcomes: A systematic review and meta-
493 analysis. *Reviews in Medical Virology*. 2023;33(1):e2365.
- 494 11. Reukers D, van Asten L, Hooiveld M, Jongenotter F, de Lange M, Teirlinck A, et al. Surveillance
495 of acute respiratory infections in the Netherlands: winter 2022/2023. SARS-CoV-2, influenza virus, RSV
496 and other respiratory viruses. *Surveillance van acute luchtweginfecties in Nederland: winter 2022/2023:*
497 *Rijksinstituut voor Volksgezondheid en Milieu RIVM*; 2023.
- 498 12. Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. Changes in Influenza and Other
499 Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021. *MMWR Morb*
500 *Mortal Wkly Rep*. 2021;70(29):1013-9.
- 501 13. Tang CY, Boftsi M, Staudt L, McElroy JA, Li T, Duong S, et al. SARS-CoV-2 and influenza co-
502 infection: A cross-sectional study in central Missouri during the 2021–2022 influenza season. *Virology*.
503 2022;576:105-10.
- 504 14. Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and
505 outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review
506 and meta-analysis. *PloS one*. 2021;16(5):e0251170.
- 507 15. Eldesouki RE, Uhteg K, Mostafa HH. The circulation of Non-SARS-CoV-2 respiratory viruses and
508 coinfections with SARS-CoV-2 during the surge of the Omicron variant. *Journal of Clinical Virology*.
509 2022;153:105215.
- 510 16. Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. *Nature*
511 *Reviews Molecular Cell Biology*. 2022;23(1):3-20.
- 512 17. Liu D, Chen C, Chen D, Zhu A, Li F, Zhuang Z, et al. Mouse models susceptible to HCoV-229E and
513 HCoV-NL63 and cross protection from challenge with SARS-CoV-2. *Proceedings of the National Academy*
514 *of Sciences*. 2023;120(4):e2202820120.
- 515 18. Domenech de Cellès M, Goult E, Casalegno J-S, Kramer SC. The pitfalls of inferring virus–virus
516 interactions from co-detection prevalence data: application to influenza and SARS-CoV-2. *Proceedings*
517 *of the Royal Society B*. 2022;289(1966):20212358.

- 518 19. Dee K, Goldfarb DM, Haney J, Amat JAR, Herder V, Stewart M, et al. Human Rhinovirus Infection
519 Blocks Severe Acute Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium:
520 Implications for COVID-19 Epidemiology. *J Infect Dis.* 2021;224(1):31-8.
- 521 20. Essaidi-Laziosi M, Alvarez C, Puhach O, Sattonnet-Roche P, Torriani G, Tapparel C, et al.
522 Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in
523 the upper respiratory tract. *Emerging Microbes & Infections.* 2022;11(1):413-24.
- 524 21. Waterlow NR, van Leeuwen E, Davies NG, Group CC-W, Flasche S, Eggo RM. How immunity from
525 and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology. *Proceedings of the*
526 *National Academy of Sciences.* 2021;118(49):e2108395118.
- 527 22. Wratil PR, Schmacke NA, Karakoc B, Dulovic A, Junker D, Becker M, et al. Evidence for increased
528 SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal
529 coronaviruses. *Cell Rep.* 2021;37(13):110169.
- 530 23. Chin T, Foxman EF, Watkins TA, Lipsitch M. Considerations for viral co-infection studies in human
531 populations. *mBio.* 2024;15(7):e00658-24.

532

533